Bugula  Bugula is a genus of common colonial arborescent bryozoa, often mistaken for seaweed. It commonly grows upright in bushy colonies of up to 15 cm in height. The native distribution of "Bugula neritina" is presumed to be tropical and subtropical waters; however it has become widespread globally due to attachment to the hulls of vessels. It is considered an invasive species in some countries. Bugula neritina attracted interest as a source of cytotoxic chemicals, bryostatins, under clinical investigation as anti-cancer agents. It was first collected and provided to JL Hartwell’s anticancer drug discovery group at the National Cancer Institute (NCI) by Jack Rudloe. In 2001 pharmaceutical company GPC Biotech licensed Bryostatin 1 from Arizona State University for commercial development as a treatment for cancer. GPC Biotech canceled development in 2003, saying that Bryostatin 1 showed little effectiveness and some toxic side-effects. More recent work shows it has positive effects on cognition in sufferers of Alzheimers with few side effects. Dried "Bugula" are commonly used as decorations: "Air fern", the so-called everlasting plant that supposedly absorbs from air all the moisture it needs to live, is commonly dried colonies of the bryozoan "Bugula" that have been artificially coloured. However, "Sertularia argentea" are also sold as "air ferns."